Health Condition 1: - Health Condition 2: H181- Bullous keratopathy Health Condition 3: H00-H59- Diseases of the eye and adnexa
Conditions
Interventions
Intervention1: Ripasudil hydrochloride Hydrate 0.4% eye drops instilled as single drop twice daily in the eye along with standard medical management of post cataract surgery corneal edema: All patient
Sponsors
Office of Director General Armed Forces Medical Services
Eligibility
Inclusion criteria
Inclusion criteria: Patients who develop immediate corneal edema, that is, corneal edema observed on day one after undergoing cataract surgery would be initially enrolled in the study.
Exclusion criteria
Exclusion criteria: Pre-operative factors Eyes with advanced retinal pathology, corneal pathology such as dystrophies, degenerations or prior corneal trauma with residual scarring Chronic diagnosed glaucoma or ocular hypertension at baseline examination Use of any topical medication that is toxic to corneal endothelium Diabetes mellitus Immunocompromised states Postoperative complications Endophthalmitis, toxic anterior segment syndrome, postoperative rise in IOP (to >21mm Hg)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study and compare the effect of Rho kinase inhibitor Ripasudil with standard treatment versus standard treatment alone on Central Corneal Thickness(CCT) after 4 weeks, in patients with corneal edema following cataract surgery.Timepoint: Baseline, 1 week, 2 weeks, 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate and compare change in Endothelial Cell Density (ECD) after 4 weeks in the two groups.Timepoint: Baseline, 1 week, 2 weeks, 4 weeks | — |
Countries
India
Contacts
Public ContactSrujana Dubbaka
Department of Ophthalmology
Outcome results
None listed